Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
NRX Pharmaceuticals Inc
NRXPCurrent price
2.08 USD
-0.01 USD (-0.48%)
Last closed
2.18 USD
Company
www.nrxpharma.com
ISIN
US6294441000
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
14 512 921 USD
Yield for 12 month
-60.75 %
1Y
3Y
5Y
10Y
15Y
NRXP
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware. Address: 1201 Orange Street, Wilmington, DE, United States, 19801
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
31.67 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-5 000 USD
Last Year
-4 000 USD
Current Quarter
–
Last Quarter
-1 000 USD
Key Figures NRXP
1 year
3 years
5 years
10 years
EBITDA
-23 257 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-115.97 %
PEG Ratio
–
Return On Equity TTM
-682.61 %
Wall Street Target Price
31.67 USD
Revenue TTM
–
Book Value
-1.42 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-2.11 USD
Diluted Eps TTM
-2.11 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics NRXP
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History NRXP
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
02.04.2024
Stock Valuation NRXP
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-0.15
Price Book MRQ
2.90
Financials NRXP
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators NRXP
For 52 weeks
1.10 USD
7.33 USD
50 Day MA
1.28 USD
Shares Short Prior Month
667 005
200 Day MA
2.64 USD
Short Ratio
4.80
Shares Short
565 801
Short Percent
7.69 %
BeatStart